ODM 204Alternative Names: ODM-204
Latest Information Update: 25 Mar 2017
At a glance
- Originator Orion
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer